BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, April 18, 2024
Home
»
Newsletters
» BioWorld
BioWorld
Jan. 17, 2002
View Archived Issues
Inspire Comes Up Short In Phase III Study; Stock Falls 73 Percent
Inspire Pharmaceuticals Inc. said it’s not likely that the first Phase III trial of its lead product for dry eye will reach its endpoints. The negative news sent Inspire’s stock tumbling 73 percent.
Read More
Immunex’s Enbrel Continues Growth, Receives 4th Approval
Read More
Merck Conducting Human Safety Trials Of Anti-HIV T-Lymphocyte Killers; No Antibodies Need Apply
Read More
Zonagen Opts To Move Forward Rather Than Explore Alternatives
Read More
Other News To Note
Read More
Correction/Clarification
Read More
La Jolla Raises $51.6M Privately To Fund Late-Stage Clinical Trials
Read More